Literature DB >> 18028255

Making sense of neuroimaging in psychiatry.

G S Malhi1, J Lagopoulos.   

Abstract

OBJECTIVE: Neuroimaging of psychiatric disorders has increased exponentially in the last decade; however, much of the uptake thus far has been in the realm of research. We anticipate that clinical use of neuroimaging modalities in psychiatry will increase dramatically in the near future and suggest that clinicians need to be aware of the potential applications.
METHOD: The authors conducted an extensive MEDLINE, EMBASE, PubMED and PsychInfo search of the published literature (1965-2007) using a variety of search terms to find relevant articles. Bibliographies of retrieved papers were further scrutinised for publications of interest, as were indices of books. Articles that reported clinically significant findings and research reports conducted using pertinent neuroimaging modalities were reviewed in detail.
RESULTS: The review suggests that exciting neuroimaging advances are being made that have relevance to psychiatry. Novel neuroimaging applications with potential clinical utility are rapidly emerging and the accessibility and use of these technologies will increase in coming years. Clinically meaningful findings have begun to emerge in mood disorders, post-traumatic stress disorder, schizophrenia and dementia. Coupling multimodal imaging with genetics and pharmacotherapeutic studies will further assist in understanding the pathophysiology of neuropsychiatric disorders.
CONCLUSION: It is important that clinicians understand the benefits and limitations of modern neuroimaging techniques and are also suitably equipped to appraise future developments. The use of neuroimaging in evaluating psychopathology is likely to impact upon the future nosology of psychiatric disorders, and assist in diagnosis and clinical management. The integrated use of neuroimaging in conjunction with clinical assessments promises to improve clinical care and markedly alter psychiatric practice.

Entities:  

Mesh:

Year:  2007        PMID: 18028255     DOI: 10.1111/j.1600-0447.2007.01111.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  14 in total

1.  Changes in Cerebral Cortex and Limbic Brain Functions after Short-Term Paroxetine Treatment in Panic Disorder: An [F]FDG-PET Pilot Study.

Authors:  Hyun-Bo Sim; Eun-Ho Kang; Bum-Hee Yu
Journal:  Psychiatry Investig       Date:  2010-08-13       Impact factor: 2.505

Review 2.  The neural circuitry of restricted repetitive behavior: Magnetic resonance imaging in neurodevelopmental disorders and animal models.

Authors:  B J Wilkes; M H Lewis
Journal:  Neurosci Biobehav Rev       Date:  2018-05-23       Impact factor: 8.989

Review 3.  Psychiatric aspects of brain tumors: A review.

Authors:  Subramoniam Madhusoodanan; Mark Bryan Ting; Tara Farah; Umran Ugur
Journal:  World J Psychiatry       Date:  2015-09-22

Review 4.  Schizophrenia: from genes to phenes to disease.

Authors:  Charlotte L Allan; Alastair G Cardno; Peter McGuffin
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

Review 5.  Multisite neuroimaging trials.

Authors:  John Darrell Van Horn; Arthur W Toga
Journal:  Curr Opin Neurol       Date:  2009-08       Impact factor: 5.710

6.  Brain magnetic resonance imaging: perception and expectations of neurologists, neurosurgeons and psychiatrists.

Authors:  Paulo Branco; Margarida Ayres-Basto; Pedro Portugal; Isabel Ramos; Daniela Seixas
Journal:  Neuroradiol J       Date:  2014-06-17

Review 7.  Biological markers in noninvasive brain stimulation trials in major depressive disorder: a systematic review.

Authors:  Thiago M Fidalgo; J Leon Morales-Quezada; Guilherme S C Muzy; Noelle M Chiavetta; Mariana E Mendonca; Marcus V B Santana; Oscar F Goncalves; Andre R Brunoni; Felipe Fregni
Journal:  J ECT       Date:  2014-03       Impact factor: 3.635

8.  Data sharing in neuroimaging research.

Authors:  Jean-Baptiste Poline; Janis L Breeze; Satrajit Ghosh; Krzysztof Gorgolewski; Yaroslav O Halchenko; Michael Hanke; Christian Haselgrove; Karl G Helmer; David B Keator; Daniel S Marcus; Russell A Poldrack; Yannick Schwartz; John Ashburner; David N Kennedy
Journal:  Front Neuroinform       Date:  2012-04-05       Impact factor: 4.081

Review 9.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

10.  Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.

Authors:  Zhenhe Zhou; Hongmei Zhu; Lin Chen
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.